152 related articles for article (PubMed ID: 35218604)
1. Evaluation of the pharmacokinetics of trazpiroben (TAK-906) in the presence and absence of the proton pump inhibitor esomeprazole.
Kaur Mukker J; Dukes G; Wang L; Huh S; Khudyakov P; Nishihara M; Chen C
Clin Transl Sci; 2022 May; 15(5):1281-1290. PubMed ID: 35218604
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics of oral trazpiroben (TAK-906) after organic anion transporting polypeptide 1B1/1B3 inhibition: A phase I, randomized study.
Mukker JK; Dukes G; Tolkoff M; Wang L; Almansa C; Huh SY; Nishihara M; Ramsden D; Chen C
Clin Transl Sci; 2022 Jun; 15(6):1532-1543. PubMed ID: 35460165
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D
Chen C; Zhang W; Bari M; Almansa C; Baratta M; Rosario M
Clin Pharmacol; 2021; 13():145-155. PubMed ID: 34285598
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers.
Choi Y; Han H; Shin D; Lim KS; Yu KS
Drug Des Devel Ther; 2015; 9():4127-35. PubMed ID: 26257511
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the Safety, Tolerability, and Disposition of Trazpiroben, a D
Yamaguchi T; Kudou K; Okamoto H; Chen C; Whiting R; Sekino H
Clin Pharmacol Drug Dev; 2022 Jun; 11(6):695-706. PubMed ID: 34967147
[TBL] [Abstract][Full Text] [Related]
6. Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D
Whiting RL; Darpo B; Chen C; Fletcher M; Combs D; Xue H; Stoltz RR
Clin Pharmacol Drug Dev; 2021 Aug; 10(8):927-939. PubMed ID: 33462988
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Proton Pump Inhibitor Esomeprazole on Crizotinib Pharmacokinetics in Healthy Participants.
Xu H; O'Gorman M; Matschke K; Boutros T; Brega N; Tan W; Bello A
Clin Pharmacol Drug Dev; 2022 Jan; 11(1):34-42. PubMed ID: 34825782
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic study of esomeprazole in the elderly.
Hasselgren G; Hassan-Alin M; Andersson T; Claar-Nilsson C; Röhss K
Clin Pharmacokinet; 2001; 40(2):145-50. PubMed ID: 11286324
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study.
Shin JS; Lee JY; Cho KH; Park HL; Kukulka M; Wu JT; Kim DY; Park SH
Aliment Pharmacol Ther; 2014 Sep; 40(5):548-61. PubMed ID: 25041486
[TBL] [Abstract][Full Text] [Related]
10. Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazole.
Pohl O; Osterloh I; Lecomte V; Gotteland JP
Int J Clin Pharmacol Ther; 2013 Jan; 51(1):26-33. PubMed ID: 23110788
[TBL] [Abstract][Full Text] [Related]
11. Non-Clinical Safety Pharmacology Evaluations of Trazpiroben (TAK-906), a Novel Dopamine D
Kreckler L; Osinski M; Williams S; Whiting R
J Exp Pharmacol; 2022; 14():43-57. PubMed ID: 35173492
[TBL] [Abstract][Full Text] [Related]
12. Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers.
Zhou J; Quinlan M; Glenn K; Boss H; Picard F; Castro H; Sellami D
Br J Clin Pharmacol; 2016 Oct; 82(4):1022-9. PubMed ID: 27277189
[TBL] [Abstract][Full Text] [Related]
13. Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK-906), a dopamine D
Kuo B; Scimia C; Dukes G; Zhang W; Gupta S; Chen C; Chuang E; Camilleri M
Aliment Pharmacol Ther; 2021 Aug; 54(3):267-280. PubMed ID: 34148244
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Evaluation of the Effects of Trazpiroben (TAK-906), a Novel, Potent Dopamine D
Whiting RL; Choppin A; Luehr G; Jasper JR
J Pharmacol Exp Ther; 2021 Oct; 379(1):85-95. PubMed ID: 34253646
[TBL] [Abstract][Full Text] [Related]
15. Oral esomeprazole in Japanese pediatric patients with gastric acid-related disease: Safety, efficacy, and pharmacokinetics.
Shimizu T; Nakayama Y; Ishii E; Ida S; Satou T; Tokuhara D; Arai K; Nii M; Rydholm H; Yajima T;
Pediatr Int; 2019 Jan; 61(1):87-95. PubMed ID: 30422368
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the drug-drug interaction potential for trazpiroben (TAK-906), a D
Nishihara M; Ramsden D; Balani SK
Xenobiotica; 2021 Jun; 51(6):668-679. PubMed ID: 33879032
[TBL] [Abstract][Full Text] [Related]
17. Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects.
Kraft WK; Chang PS; van Iersel ML; Waskin H; Krishna G; Kersemaekers WM
Antimicrob Agents Chemother; 2014 Jul; 58(7):4020-5. PubMed ID: 24798274
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the pharmacokinetic interaction between lesogaberan (AZD3355) and esomeprazole in healthy subjects.
Niazi M; Silberg DG; Miller F; Ruth M; Holmberg AA
Drugs R D; 2010; 10(4):243-51. PubMed ID: 21171670
[TBL] [Abstract][Full Text] [Related]
19. Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
Kletzl H; Giraudon M; Ducray PS; Abt M; Hamilton M; Lum BL
Anticancer Drugs; 2015 Jun; 26(5):565-72. PubMed ID: 25643050
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and Pharmacodynamics of Esomeprazole/Sodium Bicarbonate Immediate-Release Capsules in Healthy Chinese Volunteers: A Cross-Over, Randomized Controlled Trial.
Jing S; Zhu Y; Liu W; Yang K; Hu L; Deng D; Lu C; Lin Y
Adv Ther; 2021 Mar; 38(3):1660-1676. PubMed ID: 33575950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
